Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Accounts Payables: 2010-2025

Historic Accounts Payables for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $31.2 million.

  • Iovance Biotherapeutics' Accounts Payables was N/A to $31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.2 million, marking a year-over-year change of. This contributed to the annual value of $27.5 million for FY2024, which is 16.95% down from last year.
  • Per Iovance Biotherapeutics' latest filing, its Accounts Payables stood at $31.2 million for Q3 2025, which was down 2.40% from $32.0 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Accounts Payables registered a high of $33.1 million during Q4 2023, and its lowest value of $19.3 million during Q3 2023.
  • In the last 3 years, Iovance Biotherapeutics' Accounts Payables had a median value of $31.2 million in 2023 and averaged $28.9 million.
  • Per our database at Business Quant, Iovance Biotherapeutics' Accounts Payables dropped by 18.60% in 2024 and then grew by 10.85% in 2025.
  • Iovance Biotherapeutics' Accounts Payables (Quarterly) stood at $33.1 million in 2023, then decreased by 16.95% to $27.5 million in 2024, then rose by 10.85% to $31.2 million in 2025.
  • Its Accounts Payables stands at $31.2 million for Q3 2025, versus $32.0 million for Q2 2025 and $28.5 million for Q1 2025.